Camille DeLuca-Flaherty, Ph.D., is Director of Research Operations for Exelixis, Inc., responsible for coordination, reporting and organizational development of R&D programs, resources, budget and corporate services/administration interfaces. Dr. DeLuca-Flaherty joined Exelixis in 1998 as Program Manager for the Exelixis-Bayer AG partnership. Dr. DeLuca-Flaherty was previously Senior Research Scientist/Group Leader at Affymax Research Institute. Prior to joining Affymax she was at Sandoz Crop Protection, Inc, progressing from Research Scientist to Senior Scientist and Project Leader. Dr. DeLuca-Flaherty received her Ph. D. from the University of Colorado and was a postdoctoral fellow in the laboratory of Dr. David McKay of Stanford University.  

Dr. Mather has over thirty years of experience in cell biology research and development. She obtained her PhD, and did postdoctoral work, at the UC San Diego. After a year as an NIH/INSERM Exchange Scientist in Lyon, France, Dr. Mather joined the faculty of The Rockefeller University. In 1984, she joined Genentech, as a Senior Scientist in Process Sciences and was promoted to Staff Scientist in 1988. She was involved in designing cell culture production processes for 4 currently marketed products, including Herceptin and Activase. In 1994, she and her group joined the Research division of Genentech where, as a Research Staff Scientist, she initiated discovery research projects in the areas of neurobiology, endocrinology, and oncology and contributed to a genomics screening effort. While at Genentech, Dr. Mather was a member of more than 12 project teams. This has given her exposure to most aspects of biotechnology product development, from the initial assessment of ideas, to forming and leading a team through the research, and early development phases of a new drug.

In Jan 1999, Dr. Mather left Genentech to found Raven Biotechnologies, Inc. a company whose mission is the rapid and focused simultaneous discovery of cancer drug targets and therapeutic monoclonal antibodies using an integrated cell-based approach to drug discovery. Dr. Mather has been named inventor on more than 25 patents and has authored or edited 5 books, including Introduction to Cell and Tissue Culture, and more than 150 publications. Dr. Mather also serves on the Scientific Advisory Boards of Guava Technologies and CellStat Technologies.

As Founder, President and CEO, she has raised $23 million in equity investment and grown Raven biotechnologies from its inception to its current size of 48 people. Raven currently has more than 40 antibodies for the treatment of cancer in the pipeline. In 2001, Dr Mather became a member of the Emerging Companies Section Governing Body of the Biotechnology Industry Organization. In 2002, Dr. Mather was named one of the top 10 Innovators by Red Herring Magazine.

 

Dr. Perlman joined Affymax as Chief Executive Officer from Tularik, Inc., where he most recently served as Executive Vice President. Over the last decade, he has been instrumental in Tularik's evolution to a mature drug discovery and development company with multiple products in the clinic. He also played a major role in preparing the company for its successful public offerings in 1999 and 2000. Dr. Perlman's previous positions at Tularik were as Vice President of Medical Research and Corporate Development. Before joining Tularik, Dr. Perlman spent five years in several senior clinical development positions at Genentech, Inc. where he was responsible for designing, implementing and analyzing clinical trials and filing New Drug Applications (NDAs) for U.S. Food and Drug Administration marketing approval. He was also responsible for Genentech's patient registry known as the National Cooperative Growth Study.

Earlier in his career, Dr. Perlman was a faculty member in the Department of Medicine at Stanford University where he conducted research on the genetic regulation of blood pressure and authored many scientific articles and chapters in medical texts.

Dr. Perlman is a member of the Board of Directors of SangStat Medical Corporation. He received his M.D. and Ph.D. from New York University in 1975.